Immunovant Inc [IMVT] stock is trading at $26.73, up 3.20%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The IMVT shares have gain 5.44% over the last week, with a monthly amount glided 17.03%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Immunovant Inc [NASDAQ: IMVT] stock has seen the most recent analyst activity on January 06, 2026, when Wolfe Research upgraded its rating to an Outperform but kept the price target unchanged to $50 for it. Previously, Truist started tracking the stock with Hold rating on October 14, 2025, and set its price target to $16. Jefferies started tracking the stock assigning a Hold rating and suggested a price target of $20 on March 03, 2025. Wolfe Research downgraded its rating to a Peer Perform. In a note dated October 09, 2024, Oppenheimer reiterated an Outperform rating on this stock and boosted its target price from $47 to $53.
Immunovant Inc [IMVT] stock has fluctuated between $12.72 and $27.69 over the past year. Currently, Wall Street analysts expect the stock to reach $35.67 within the next 12 months. Immunovant Inc [NASDAQ: IMVT] shares were valued at $26.73 at the most recent close of the market. An investor can expect a potential return of 33.45% based on the average IMVT price forecast.
Analyzing the IMVT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.8, Equity is -0.85 and Total Capital is -0.94.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 25.96 points at the first support level, and at 25.19 for the second support level. However, for the 1st resistance point, the stock is sitting at 27.44, and for the 2nd resistance point, it is at 28.14.
Ratios To Look Out For
For context, Immunovant Inc’s Current Ratio is 9.07. As well, the Quick Ratio is 9.07, while the Cash Ratio is 8.25.
Transactions by insiders
Recent insider trading involved Van Tuyl Christopher, Chief Legal Officer, that happened on Dec 18 ’25 when 10813.0 shares were sold. Director, Roivant Sciences Ltd. completed a deal on Dec 12 ’25 to buy 16.67 million shares. Meanwhile, Director Fromkin Andrew J. sold 22249.0 shares on Dec 01 ’25.
